PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry

Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler, Lothar Häberle, Sabrina Uhrig, Chloë Goossens, Niklas Amann, Jan-Philipp Cieslik, Lara M. Tretschock, Dominik Dannehl, Thomas M. Deutsch, Moritz Dimpfl, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Melitta B. Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Lea Sych, Nikolas Tauber, Christian M. Tegeler, Catharina Wichmann, Maggie Banys-Paluchowski, Henriette Princk, Achim Rody, Sara Y. Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Carolin C. Hack, Peyman Hadji, Alexander Hein, Wolfgang W. Janni, Hans-Christian Kolberg, Diana Lüftner, Michael P. Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch, Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Erik Belleville, Laura L. Michel, Markus Wallwiener, Peter A. Fasching, Andreas Schneeweiss, Christian Maurer

Open source

DOI: 10.1038/s41523-026-00947-8
Published: 2026-04-11
Container: npj Breast Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41523-026-00947-8,
  title = {PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry},
  author = {Manuel Hörner and Andreas Hartkopf and Nelson John and Philipp Ziegler and Lothar Häberle and Sabrina Uhrig and Chloë Goossens and Niklas Amann and Jan-Philipp Cieslik and Lara M. Tretschock and Dominik Dannehl and Thomas M. Deutsch and Moritz Dimpfl and Max Ehlert and Kathleen Eichstädt and Alexander Englisch and Melitta B. Köpke and Annika Krückel and Theresa Link and Annika Müller and Kristin Reinhardt and Jonas Roth and Henning Schäffler and Lea Sych and Nikolas Tauber and Christian M. Tegeler and Catharina Wichmann and Maggie Banys-Paluchowski and Henriette Princk and Achim Rody and Sara Y. Brucker and Nina Ditsch and Johannes Ettl and Tanja Fehm and Carolin C. Hack and Peyman Hadji and Alexander Hein and Wolfgang W. Janni and Hans-Christian Kolberg and Diana Lüftner and Michael P. Lux and Volkmar Müller and Florin-Andrei Taran and Hans Tesch and Diethelm Wallwiener and Frederik Marmé and Stephan Seitz and Erik Belleville and Laura L. Michel and Markus Wallwiener and Peter A. Fasching and Andreas Schneeweiss and Christian Maurer},
  year = {2026},
  journal = {npj Breast Cancer},
  doi = {10.1038/s41523-026-00947-8},
  url = {https://doi.org/10.1038/s41523-026-00947-8}
}

RIS

TY  - JOUR
TI  - PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
AU  - Manuel Hörner
AU  - Andreas Hartkopf
AU  - Nelson John
AU  - Philipp Ziegler
AU  - Lothar Häberle
AU  - Sabrina Uhrig
AU  - Chloë Goossens
AU  - Niklas Amann
AU  - Jan-Philipp Cieslik
AU  - Lara M. Tretschock
AU  - Dominik Dannehl
AU  - Thomas M. Deutsch
AU  - Moritz Dimpfl
AU  - Max Ehlert
AU  - Kathleen Eichstädt
AU  - Alexander Englisch
AU  - Melitta B. Köpke
AU  - Annika Krückel
AU  - Theresa Link
AU  - Annika Müller
AU  - Kristin Reinhardt
AU  - Jonas Roth
AU  - Henning Schäffler
AU  - Lea Sych
AU  - Nikolas Tauber
AU  - Christian M. Tegeler
AU  - Catharina Wichmann
AU  - Maggie Banys-Paluchowski
AU  - Henriette Princk
AU  - Achim Rody
AU  - Sara Y. Brucker
AU  - Nina Ditsch
AU  - Johannes Ettl
AU  - Tanja Fehm
AU  - Carolin C. Hack
AU  - Peyman Hadji
AU  - Alexander Hein
AU  - Wolfgang W. Janni
AU  - Hans-Christian Kolberg
AU  - Diana Lüftner
AU  - Michael P. Lux
AU  - Volkmar Müller
AU  - Florin-Andrei Taran
AU  - Hans Tesch
AU  - Diethelm Wallwiener
AU  - Frederik Marmé
AU  - Stephan Seitz
AU  - Erik Belleville
AU  - Laura L. Michel
AU  - Markus Wallwiener
AU  - Peter A. Fasching
AU  - Andreas Schneeweiss
AU  - Christian Maurer
PY  - 2026
JO  - npj Breast Cancer
DO  - 10.1038/s41523-026-00947-8
UR  - https://doi.org/10.1038/s41523-026-00947-8
ER  -

APA

Hörner, M., Hartkopf, A., John, N., Ziegler, P., Häberle, L., Uhrig, S., Goossens, C., Amann, N., Cieslik, J., Tretschock, L. M., Dannehl, D., Deutsch, T. M., Dimpfl, M., Ehlert, M., Eichstädt, K., Englisch, A., Köpke, M. B., Krückel, A., Link, T., Müller, A., Reinhardt, K., Roth, J., Schäffler, H., Sych, L., Tauber, N., Tegeler, C. M., Wichmann, C., Banys-Paluchowski, M., Princk, H., Rody, A., Brucker, S. Y., Ditsch, N., Ettl, J., Fehm, T., Hack, C. C., Hadji, P., Hein, A., Janni, W. W., Kolberg, H., Lüftner, D., Lux, M. P., Müller, V., Taran, F., Tesch, H., Wallwiener, D., Marmé, F., Seitz, S., Belleville, E., Michel, L. L., Wallwiener, M., Fasching, P. A., Schneeweiss, A., & Maurer, C. (2026). PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry. npj Breast Cancer. https://doi.org/10.1038/s41523-026-00947-8

Source records

crossref · retrieved 2026-09-26T05:27:09.562Z